Republic of the Philippines

Cebu Normal University

Osmeña Blvd. Cebu City, 6000 Philippines

College of Nursing
Center of Excellence (COE) | Level IV Re-Accredited (AACCUP)
Telephone No.: (032) 254 4837
Email: cn@cnu.edu.ph/secretary@cnunursing.org
Website: www.cnu.edu.ph
DRUG STUDY

Patient’s Initials:______________________________________ Date of Admission:_________________________________________ Diagnosis:____________________________________________

Age:__________________________________________________ Height/Weight:_____________________________________________ Clinical Intervention:
_________________________________
Sex:__________________________________________________ Ward:________ Bed No.:________ Name of Physician: __________________________________

Nursing
Name of Drug Classification Mechanism of Action Indication Contraindication Side Effects
Responsibilities
Generic Name: Pharmacologic Class: Magnesium sulfate has General Indications: 1. Parenteral 1. Reduced respiratory Before
Magnesium Sulfate Mineral/Electrolyte CNS and respiratory 1. Acute nephritis administration of drug rate 1. Verify doctor’s order
depressant effects where (children), to control contraindicated in 2. Decreased reflexes on the administration of
Trade/Brand Name: it causes vasodilation hypertension patients with heart block 3. flushing drug.
Epsom salt, magnesium Therapeutic Class: resulting to flushing and 2. IV- or myocardial damage. 4. Hypotension 2. Inform the patient
sulfate injection Anticonvulsant, antacid, sweating or adverse Hypomagnesemia, This is used cautiously to 5. Decreased heart rate about the drug that is
electrolyte, laxative effects, hypotension. replacement therapy patients who have renal about to be administered.
Route: 3. IV or IM- Pre- impairment and women Adverse effects: 3. Inform patient on the
IV, IM, PO It blocks neuromuscular eclampsia or eclampsia in labor as this may be potential side and
Pregnancy Risk transmission, amount of 4. PO- short-term distributed in the CNS adverse effects of the
Form: Category: acetylcholine release at treatment of breastmilk for 24 hours drug.
Solution motor end plate, constipation, evacuation after therapy is 1. Weakness 4. Assess for sensitivity
Category A therefore, works as a of the colon for rectal discontinued. This also 2. Dizziness to magnesium, renal
Maximum dose: Category B (Laxative) seizure control. It also and bowel eliminations readily crosses the 3. Fainting function and serum
Hypomagnesemia: attracts and retains water 5. To correct or prevent placenta and may 4. Sweating magnesium levels.
in the intestinal lumen hypomagnesemia in increase the risk of Assess as well for heart
IV (Adults, Elderly):1-4 and distends the bowel to patients on parenteral magnesium toxicity in Cardiovascular block, myocardial
g as 1g/hour (Mild to promote mass movement nutrition neonate. damage, symptoms of
moderate) and relieve constipation. 2. Allergy to magnesium Palpitation appendicitis, acute
Unlabeled use: products surgical abdomen, fecal
IV (Children): 25-50 Absorption: 1. Inhibition of 3. Abdominal pain GI impaction, intestinal and
mg/kg/dose over 10-20 premature labor 4. Nausea biliary tract obstruction,
minutes There is minimal slow 2. Adjunct treatment of 5. Vomiting 1. Excessive bowel and hepatitis.
 absorption of most exacerbations of acute 6. Other symptoms of activity 5. Prepare needed
IV/IM (Neonates): 25-50 cathartics, but up to 20% asthma appendicitis 2. Perianal irritation materials for the drug
mg/kg/dose q8-12 hours of the magnesium in a 3. Treatment of torsades 7. Acute surgical administration.
for 2-3 doses dose of magnesium de pointes abdomen Metabolic (Magnesium
sulfate is absorbed in the 4. Atypical ventricular 8. Fecal impaction Intoxication) During
Eclampsia/Preeclampsia small intestine. arryhtmias 9. Intestinal and biliary 1. Give IM route by deep
tract obstruction 1. Flushing IM injection of the
IV (Adults): 4-5 g Distribution: 10. Hepatitis 2. Sweating undiluted (50%) solution
infusion, then 1-2 g/hour 3. Hypotension for adults; dilute to a
continuous infusion Distributed widely Drug to Drug 4. Depressed reflexes 20% solution for
throughout the body. Interactions: 4. Flaccid paralysis children.
Minimum dose: 5. Hypothermia 2. Give oral magnesium
IV (Adults, Elderly): 12 Elimination: 1. May decrease 6. Circulatory collapse sulfate as a laxative only
g/12 hours absorption of quinolones 7. Cardiac depression as a temporary measure.
IV (Children): 2 g Urine 2. Potentiation of 8. Hypocalcemia with 3. Do not give oral
neuromuscular blockade tetany magnesium sulfate with
Eclampsia/Preeclampsia Onset: produced by abdominal pain, nausea,
nondepolarizing or vomiting.
IV (Adults): 40 g/24 1. IV- Immediate neuromuscular relaxants 4. Take or administer at
hours 2. IM- 1 hour 3. Potential for least 2 hours apart from
3. Oral- 1-2 hours hypomagnesemia if other medication.
Availability: combined with alcohol, 5. Do not take longer
1. Infusion Solution: Duration: aminoglycosides, than 2 weeks unless
10 mg/mL, 20 mg/mL, amphotericin B, directed by the
40 mg/mL, 80 mg/mL 1. IV- 30 minutes cisplatin, cyclosporine, physician.
2. IM- 3-4 hours digoxin, diuretics 6. For peptic ulcer, take 1
2. Injection Solution 3. Oral- 3-4 hours and 3 hours after meals
125 mg/mL, 500 mg/mL and at bedtime for 4-6
Half-life: weeks.
Content: 7. Chew tablets
Each mL: Unknown thoroughly, followed by
8 oz of water; shake
1. Magnesium Sulfate suspensions well.
2. Heptahydrate (4.06
mEq each of Magnesium After
and Sulfate) 1. Monitor for renal
3. Water function, magnesium
levels, and EKG for
cardiac function.
2. Test patellar reflexes
before giving repeated,
rapid parenteral doses.
3. Initiate seizure
precautions.
4. Instruct patient and
 family to report for
symptoms of
hypermagnesemia such
as altered mentation,
difficulty in breathing,
dizziness, fatigue,
palpitations, and
weakness.

Source: Source:
Karch, A. M. (2014). Source: Karch, A. M. (2014).
Source: Source: Source: 2014 Lippincott's Karch, A. M. (2014). Source: 2014 Lippincott's
Karch, A. M. (2014). Karch, A. M. (2014). Karch, A. M. (2014). Nursing Drug Guide. In 2014 Lippincott's Karch, A. M. (2014). Nursing Drug Guide. In
2014 Lippincott's 2014 Lippincott's 2014 Lippincott's A. M. Karch, Nursing Drug Guide. In 2014 Lippincott's A. M. Karch,
Nursing Drug Guide. In Nursing Drug Guide. In Nursing Drug Guide. In Lippincott's Nursing A. M. Karch, Nursing Drug Guide. In Lippincott's Nursing
A. M. Karch, Lippincott's A. M. Karch, A. M. Karch, Drug Guide (pp. 718- Lippincott's Nursing A. M. Karch, Drug Guide (pp. 718-
Nursing Drug Guide (pp. Lippincott's Nursing Lippincott's Nursing 720). China: Wolters Drug Guide (pp. 718- Lippincott's Nursing 720). China: Wolters
718-720). China: Wolters Drug Guide (pp. 718- Drug Guide (pp. 718- Kluwer. 720). China: Wolters Drug Guide (pp. 718- Kluwer.
Kluwer. 720). China: Wolters 720). China: Wolters Kluwer. 720). China: Wolters
Kluwer. Kluwer. Kizior, R. J., & Kluwer. Kizior, R. J., & Hodgson,
Kizior, R. J., & Hodgson, Hodgson, K. J. (2019). Kizior, R. J., & K. J. (2019). Saunders
K. J. (2019). Saunders Kizior, R. J., & Kizior, R. J., & Saunders Nursing Drug Hodgson, K. J. (2019). Kizior, R. J., & Nursing Drug Handbook
Nursing Drug Handbook Hodgson, K. J. (2019). Hodgson, K. J. (2019). Handbook 2019. In R. J. Saunders Nursing Drug Hodgson, K. J. (2019). 2019. In R. J. Kizior , &
2019. In R. J. Kizior , & Saunders Nursing Drug Saunders Nursing Drug Kizior , & K. J. Handbook 2019. In R. J. Saunders Nursing Drug K. J. Hodgson, Saunders
K. J. Hodgson, Saunders Handbook 2019. In R. J. Handbook 2019. In R. J. Hodgson, Saunders Kizior , & K. J. Handbook 2019. In R. J. Nursing Drug Handbook
Nursing Drug Handbook Kizior , & K. J. Kizior , & K. J. Nursing Drug Handbook Hodgson, Saunders Kizior , & K. J. 2019 (pp. 1627-1634).
2019 (pp. 1627-1634). Hodgson, Saunders Hodgson, Saunders 2019 (pp. 1627-1634). Nursing Drug Handbook Hodgson, Saunders St. Louis, Missouri:
St. Louis, Missouri: Nursing Drug Handbook Nursing Drug Handbook St. Louis, Missouri: 2019 (pp. 1627-1634). Nursing Drug Handbook Elsevier.
Elsevier. 2019 (pp. 1627-1634). 2019 (pp. 1627-1634). Elsevier. St. Louis, Missouri: 2019 (pp. 1627-1634).
St. Louis, Missouri: St. Louis, Missouri: Elsevier. St. Louis, Missouri:
MAGNESIUM Elsevier. Elsevier. Elsevier.
SULFATE.
(2017, January 17).
Retrieved from RxList:
https://www.rxlist.
com/magnesium-sulfate-
drug.htm#description
Drug Study Scoring 10 pts.
Name of Drug 1 pts.
Classification 1 pts.
Mechanism of Action 1 pts.
Indication 1 pts.
Contraindication 1 pts.
Side Effects 1 pts.
Nursing Responsibilities 3 pts.
Sources 1 pts. (at least 2 references)
Scoring System Criterion Reference: 70%